Our findings establish FRA1 as a potent driver of an actionable pro-metastatic transcriptional network in melanoma and potentially other cancers, offering new avenues for therapeutic intervention in advanced disease with otherwise limited treatment options. This evidence concerns the gene FOSL1 and cancer.